COMPARISON OF LIGAND-BINDING ASSAY AND ENZYME-IMMUNOASSAY OF ESTROGEN-RECEPTOR IN HUMAN BREAST-CANCER CYTOSOLS - EXPERIENCE OF THE EORTC RECEPTOR GROUP

被引:33
|
作者
BLANKENSTEIN, MA
机构
[1] Department of Endocrinology, Academic Hospital Utrecht, Utrecht, 3508 GA
关键词
ESTROGEN RECEPTOR; LIGAND BINDING ASSAY; IMMUNOASSAY; QUALITY CONTROL; CYTOSOL;
D O I
10.1007/BF01806289
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nine laboratories cooperating in the Receptor Study Group of the EORTC compared results of ligand binding assay supplemented with Scatchard plot analysis (LBA) and enzyme immunoassay (EIA) for the assessment of oestrogen receptors in 1665 breast cancer cytosols. An excellent agreement was observed between results of Scatchard plot analysis and EIA in each laboratory. Linear correlation coefficients of log-transformed data (log ](ER + 10)/10[) ranged from 0.839 to 0.977 (n = 52-373; P < 0.001); Spearman's R ranged from 0.797 to 0.972 (P < 0.001). Orthogonal regression analysis on log-transformed data revealed slopes of 0.794 to 1.141 and intercepts of -0.057 to 0.154 corresponding to -1.2 to 4.3 fmole/mg protein. Both assays compared equally well for pre- as well as postmenopausal patients, which confirms that occupied receptors are not extracted during the preparation of cytosol. The percentage discordance in the classification of tumours as ER positive or negative varied from 4.1 to 13.3 when a cut-off value of 10 fmol/mg protein was used, and from 1.4 to 7.5 at a cut-off level of 20. Considerable variations were observed in the actual receptor levels reported by each laboratory. Since these differences occurred in the results of both methods, they are attributed to differences in tissue handling. It is concluded that the ER-EIA is an excellent alternative to Scatchard plot analysis for the assay of oestrogen receptors. It is recommended, however, that laboratories performing assays on samples obtained from patients who are eligible for entrance in EORTC clinical trials and who wish to use the EIA should validate this assay against the Scatchard plot assay in their own setting.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 31 条
  • [1] ESTROGEN-RECEPTOR DETERMINATION IN ENDOMETRIAL CARCINOMA - LIGAND-BINDING ASSAY VERSUS ENZYME-IMMUNOASSAY
    NYHOLM, HCJ
    NIELSEN, AL
    LYNDRUP, J
    GREENE, GL
    THORPE, SM
    ANTICANCER RESEARCH, 1995, 15 (02) : 649 - 654
  • [2] Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison
    Marc Lacroix
    Gilbert Querton
    Philippe Hennebert
    Denis Larsimont
    Guy Leclercq
    Breast Cancer Research and Treatment, 2001, 67 : 263 - 271
  • [3] Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison
    Lacroix, M
    Querton, G
    Hennebert, P
    Larsimont, D
    Leclercq, G
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 67 (03) : 263 - 271
  • [4] ESTROGEN-RECEPTOR FUNCTIONAL STATUS IN HUMAN BREAST-CANCER
    TRAISH, AM
    NEWTON, AW
    STYPEREK, K
    BEAZLEY, R
    KAVANAH, M
    DIAGNOSTIC MOLECULAR PATHOLOGY, 1995, 4 (03) : 220 - 228
  • [5] ESTROGEN-RECEPTOR ASSAY OF BREAST-CANCER BY IMMUNOCYTOCHEMISTRY OF FINE NEEDLE ASPIRATES
    KITCHEN, PRB
    STILLWELL, RG
    HENDERSON, MA
    BENNETT, RC
    RENNIE, GC
    KOU, SJ
    GEORGIOU, T
    AYBERK, H
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1991, 61 (03): : 223 - 228
  • [6] DETERMINATION OF ESTROGEN-RECEPTORS USING ENZYME-IMMUNOASSAY AND RADIOLIGAND BINDING ASSAY IN 2 134 BREAST-CANCER TUMORS
    ROMAIN, S
    DUSSERT, C
    MARTIN, PM
    BULLETIN DU CANCER, 1991, 78 (04) : 331 - 340
  • [7] UP-REGULATION OF ESTROGEN-RECEPTOR BY TAMOXIFEN IN HUMAN BREAST-CANCER
    NOGUCHI, S
    MOTOMURA, K
    INAJI, H
    IMAOKA, S
    KOYAMA, H
    CANCER, 1993, 71 (04) : 1266 - 1272
  • [8] Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Gonzalez, Thomas L.
    Hancock, Molly
    Sun, Siqi
    Gersch, Christina L.
    Larios, Jose M.
    David, Waddie
    Hu, Jiantao
    Hayes, Daniel F.
    Wang, Shaomeng
    Rae, James M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 611 - 622
  • [9] Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Thomas L. Gonzalez
    Molly Hancock
    Siqi Sun
    Christina L. Gersch
    Jose M. Larios
    Wadie David
    Jiantao Hu
    Daniel F. Hayes
    Shaomeng Wang
    James M. Rae
    Breast Cancer Research and Treatment, 2020, 180 : 611 - 622
  • [10] COMPARISON OF 4 IMMUNOCHEMICAL METHODS FOR THE MEASUREMENT OF ESTROGEN-RECEPTOR LEVELS IN BREAST-CANCER
    RYDE, CM
    SMITH, D
    KING, N
    TROTT, PA
    MACLENNAN, K
    MCKINNA, JA
    MINASIAN, H
    DOWSETT, M
    CYTOPATHOLOGY, 1992, 3 (03) : 155 - 160